Patent application number | Description | Published |
20120123232 | METHOD AND APPARATUS FOR DETERMINING HEART RATE VARIABILITY USING WAVELET TRANSFORMATION - The present invention relates to advanced signal processing methods including digital wavelet transformation to analyze heart-related electronic signals and extract features that can accurately identify various states of the cardiovascular system. The invention may be utilized to estimate the extent of blood volume loss, distinguish blood volume loss from physiological activities associated with exercise, and predict the presence and extent of cardiovascular disease in general. | 05-17-2012 |
20120136224 | Combining Predictive Capabilities of Transcranial Doppler (TCD) with Electrocardiogram (ECG) to Predict Hemorrhagic Shock - A real-time decision-support system predicts hemorrhagic shock of a patient by analysis of electrocardiogram (ECG) signals and transcranial Doppler (TCD) signals from the patient. These signals are subject to signal decomposition using Discrete Wavelet Transform (DWT) to sets of wavelet coefficients and selecting significant signal features. Machine learning is applied to the significant features to evaluate and classify hypovolemia severity based on the input ECG and TCD signals from the patient. The classification of blood loss severity is displayed in real-time. An extension of the decision-support system integrates Arterial Blood Pressure (ABP) signals and thoracic electrical bio-impedance (DZT) signals with the ECG and TCD signals from the patient to evaluate severity of hypovolemia. | 05-31-2012 |
20120143037 | Accurate Pelvic Fracture Detection for X-Ray and CT Images - Accurate pelvic fracture detection is accomplished with automated X-ray and Computed Tomography (CT) images for diagnosis and recommended therapy. The system combines computational methods to process images from two different modalities, using Active Shape Model (ASM), spline interpolation, active contours, and wavelet transform. By processing both X-ray and CT images, features which may be visible under one modality and not under the other are extracted and validates and confirms information visible in both. The X-ray component uses hierarchical approach based on directed Hough Transform to detect pelvic structures, removing the need for manual initialization. The X-ray component uses cubic spline interpolation to regulate ASM deformation during X-ray image segmentation. Key regions of the pelvis are first segmented and identified, allowing detection methods to be specialized to each structure using anatomical knowledge. The CT processing component is able to distinguish bone from other non-bone objects with similar visual characteristics, such a blood and contrast fluid, permitting detection and quantification of soft tissue hemorrhage. The CT processing component draws attention to slices where irregularities are detected, reducing the time to fully examine a pelvic CT scan. The quantitative measurement of bone displacement and hemorrhage area are used as input for a trauma decision-support system, along with physiological signals, injury details and demographic information. | 06-07-2012 |
20120184840 | Automated Measurement of Brain Injury Indices Using Brain CT Images, Injury Data, and Machine Learning - A decision-support system and computer implemented method automatically measures tee midline shift in a patient's brain using Computed Tomography (CT) images. The decision-support system and computer implemented method applies machine learning methods to features extracted from multiple sources, including midline shift, blood amount, texture pattern and other injury data, to provide a physician an estimate of intracranial pressure (ICP) levels. A hierarchical segmentation method, based on Gaussian Mixture Mode! (GMM), is used. In this approach, first an Magnetic Resonance Image (MRI) ventricle template, as prior knowledge, is used to estimate the region for each ventricle. Then, by matching the ventricle shape it) CT images to fee MRI ventricle template set, the corresponding MRI slice is selected. From the shape matching result, the feature points for midline estimation in CT slices, such as the center edge points of the lateral ventricles, are detected. The amount of shift, along with other information such as brain tissue texture features, volume of blood accumulated in the brain, patient demographics, injury information, and features extracted from physiological signals, are used to train a machine learning method to predict a variety of important clinical factors, such as intracranial pressure (ICP), likelihood of success a particular treatment, and the need and/or dosage of particular drugs. | 07-19-2012 |
20120269420 | Image Processing and Machine Learning for Diagnostic Analysis of Microcirculation - Automated quantitative analysis of microcirculation, such as density of blood vessels and red blood cell velocity, is implemented using image processing and machine learning techniques. Detection and quantification of the microvasculature is determined from images obtained through intravital microscopy. The results of quantitatively monitoring and assessing the changes that occur in microcirculation during resuscitation period assist physicians in making diagnostically and therapeutically important decisions such as determination of the degree of illness as well as the effectiveness of the resuscitation process. Advanced digital image processing methods are applied to provide quantitative assessment of video signals for detection and characterization of the microvasculature (capillaries, venules, and arterioles). The microvasculature is segmented, the presence and velocity of Red Blood Cells (RBCs) is estimated, and the distribution of blood flow in capillaries is identified for a variety of normal and abnormal cases. | 10-25-2012 |
Patent application number | Description | Published |
20080312163 | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors - This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology. | 12-18-2008 |
20090304785 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 12-10-2009 |
20090304789 | NOVEL TOPIRAMATE COMPOSITIONS AND AN ESCALATING DOSING STRATEGY FOR TREATING OBESITY AND RELATED DISORDERS - The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and a novel escalating dosing strategy for administering such compositions. | 12-10-2009 |
20100105765 | Combination Therapy For Effecting Weight Loss And Treating Obesity - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 04-29-2010 |
20100215739 | LOW DOSE TOPIRAMATE / PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF - A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. | 08-26-2010 |
20110195987 | TREATMENT WITH CHOLINERGIC AGONISTS - Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and/or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to the subject suffering from the disorders are provided. In addition, intra-vaginal administration of cholinergic agonists such as muscarinic receptor agonists to patients suffering from interstitial cystitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness is also provided. | 08-11-2011 |
20110224196 | TREATMENT OF OBSTRUCTIVE SLEEP APNEA SYNDROME WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ADDITIONAL ACTIVE AGENT - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 09-15-2011 |
20110262535 | Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof - A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. | 10-27-2011 |
20120196881 | Treatment Of Pulmonary Hypertension With Carbonic Anhydrase Inhibitors - This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology. | 08-02-2012 |
20140037723 | Low Dose Topiramate/Phentermine Composition And Methods Of Use Thereof - A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. | 02-06-2014 |
20140088162 | Treatment of Pulmonary Hypertension with Carbonic Anhydrase Inhibitors - This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology. | 03-27-2014 |
20140094511 | Treatment of Obstructive Sleep Apnea Syndrome with a Combination of a Carbonic Anhydrase Inhibitor and an Additional Active Agent - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 04-03-2014 |
20140187623 | Escalating Dosing Regimen For Effecting Weight Loss And Treating Obesity - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 07-03-2014 |
20140308346 | COMBINATION THERAPY FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 10-16-2014 |
20150025134 | Compositions and Methods for the Treatment of Sleep Apnea - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 01-22-2015 |